Author, as appears in the article.: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier
Department: Ciències Mèdiques Bàsiques Bioquímica i Biotecnologia
URV's Author/s: Avilés Jurado, Francisco Javier / Terra Barbadora, Ximena
Keywords: Tumor recurrence Tumor marker Tobacco use Retrospective study Retrospective studies Recursive partitioning Radiotherapy Prognostic factor Prognosis Primary tumor Practice guideline Neoplasm recurrence, local Multimodality cancer therapy Middle aged Male Major clinical study Local recurrence free survival Humans Human Hematological parameters Head and neck tumor Head and neck squamous cell carcinoma Head and neck neoplasms Follow up Female Disease specific survival Disease control Controlled study Cohort analysis Cisplatin Chemoradiotherapy Cetuximab Carcinoma Carboplatin Cancer surgery Cancer staging Cancer risk Cancer classification Biomarkers, tumor Ast/alt (deritis) ratio Ast Aspartic acid Aspartate aminotransferases Aspartate aminotransferase Aspartate aminotransaminase Article Alt (deritis) ratio Alanine transaminase Alanine aminotransferase Alanine aminotransaminase Alanine Adult
Abstract: Background The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy.
Methods We calculated the pre-treatment AST/ALT ratio in 670 patients with HNSCC treated with radiotherapy (n = 309, 46.1%) or chemoradiotherapy (n = 361, 53.9%).
Results Five-year local recurrence-free survival for patients with a low AST/ALT ratio value (n = 529, 79.0%) was 75.0% (95% CI: 71.1-78.9), and for patients with a high value (n = 141, 21.0%) it was 53.4% (CI 95: 44.4-62.4) (p = 0.0001). In a multivariable analysis, patients with a high ratio had nearly twice the risk of having a local tumor recurrence (HR 1.97, 95% CI 1.42-2.75, p = 0.0001).
Conclusion The AST/ALT ratio was independently associated with the risk of local recurrence in patients with HNSCC treated with radiotherapy or chemoradiotherapy.
Thematic Areas: Surgery Saúde coletiva Otorhinolaryngology Odontología Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias iv Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
licence for use: https://creativecommons.org/licenses/by/3.0/es/
Author's mail: franciscojavier.aviles@urv.cat ximena.terra@urv.cat
Author identifier: 0000-0001-5560-8097 0000-0003-1043-5844
Record's date: 2024-10-12
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://onlinelibrary.wiley.com/doi/10.1002/hed.26673
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck. 43 (7): 2091-2100
APA: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier (2021). The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck, 43(7), 2091-2100. DOI: 10.1002/hed.26673
Article's DOI: 10.1002/hed.26673
Entity: Universitat Rovira i Virgili
Journal publication year: 2021
Publication Type: Journal Publications
Repositori URV